<DOC>
	<DOCNO>NCT02038764</DOCNO>
	<brief_summary>The purpose study evaluate safety , tolerability , pharmacokinetics immunogenicity multiple dose PF-06342674 . Several dose level evaluate .</brief_summary>
	<brief_title>A Study To Assess The Safety Of PF-06342674 In Adults With Type 1 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<criteria>Women men age 18 older . Diagnosis type 1 diabetes within 2 year randomization . Peak stimulate Cpeptide level â‰¥ 0.15 ng/mL . Anticipated ongoing use diabetes medication insulin . Evidence history diabetic complication significant endorgan damage . Episode severe hypoglycemia within 60 day randomization . Multiple hospitalization diabetic ketoacidosis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Phase 1</keyword>
	<keyword>RN168</keyword>
	<keyword>Adults</keyword>
	<keyword>Type 1 Diabetes</keyword>
	<keyword>T1D</keyword>
</DOC>